Overview

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

Status:
ENROLLING_BY_INVITATION
Trial end date:
2028-06-24
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.
Phase:
PHASE3
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
eribulin
Gemcitabine
Vinorelbine